Cadre (CDRE) vs Enovis (ENOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enovis (ENOV) has outperformed Cadre (CDRE) over the past year, losing 11.5% versus a loss of 26.8%. Over five years, CDRE leads with a +51.0% price change compared with -69.5% for ENOV. Enovis is the larger company by market cap ($1.47 billion vs $1.26 billion), about 1.2 times the size, while Cadre is growing revenue faster (+7.5% vs +6.7%).
On valuation, Enovis trades at a lower forward P/E (7.4x vs 18.5x for Cadre). Cadre pays a dividend yielding 1.34%, while Enovis does not currently pay one. Cadre converts more of its revenue into profit, with a net margin of 7.2% versus -52.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDRE | ENOV |
|---|---|---|
| Share price | $29.45 | $25.47 |
| Market cap | $1.26B | $1.47B |
| 1-day change | -3.63% | -2.90% |
| YTD return | -27.89% | -4.39% |
| 1-year return | -26.83% | -11.47% |
| 5-year return | +51.03% | -69.49% |
| P/E ratio (TTM) | 32.36 | — |
| Forward P/E | 18.53 | 7.35 |
| EPS (TTM) | $0.91 | $-9.23 |
| Dividend yield | 1.34% | 0.00% |
| Annual dividend | $0.395 | $0.00 |
| Revenue (latest FY) | $610.31M | $2.25B |
| Revenue growth (YoY) | +7.53% | +6.66% |
| Net income (latest FY) | $44.14M | $-1.18B |
| Gross margin | 42.54% | 59.84% |
| Operating margin | 11.04% | -50.01% |
| Net margin | 7.23% | -52.69% |
| 52-week high | $48.76 | $31.67 |
| 52-week low | $24.07 | $16.70 |
| Distance from 52-week high | -39.60% | -19.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +59.02% | +48.53% |
| Average volume | 464.00K | 1.71M |
| Shares outstanding | 42.92M | 57.69M |
| Employees | 2,533 | 7,802 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENOV has outperformed CDRE by 15.4 percentage points over the past year.
- Cadre offers a meaningfully higher dividend yield (1.34% vs 0.00%).
- Cadre is more profitable, keeping 7.2 cents of every revenue dollar as net income versus -52.7 cents for Enovis.
About Cadre
CDRE stock →Cadre Holdings, Inc. manufactures and distributes safety equipment and other related products that provides protection to users in hazardous or life-threatening situations in the United States and internationally.
Health Care · Industrial Specialties · 2,533 employees
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
CDRE vs ENOV FAQ
Which is bigger, Cadre or Enovis?
Enovis (ENOV) is larger, with a market capitalization of $1.47B compared with $1.26B for Cadre (CDRE).
Which stock has performed better over the past year, CDRE or ENOV?
ENOV returned -11.47% over the past 12 months, compared with -26.83% for CDRE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cadre or Enovis?
Cadre pays a dividend yielding 1.34%, while Enovis does not currently pay a regular dividend.
Are Cadre and Enovis in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.